SLT decreases diurnal IOP

Article

Selective laser trabeculoplasty (SLT) can result in significant decreases in mean diurnal intraocular pressure (IOP) and diurnal IOP fluctuation, according to Gábor Holló and colleagues from the University of Budapest, Hungary.

Selective laser trabeculoplasty (SLT) can result in significant decreases in mean diurnal intraocular pressure (IOP) and diurnal IOP fluctuation, according to Gàbor Holló and colleagues from the University of Budapest, Hungary.

Twenty-six eyes of 13 primary open angle glaucoma (POAG) patients underwent a standard 360-degree SLT; the IOP curve was repeated three and six months postoperatively. IOP lowering medication was started if mean IOP was higher than 22 mmHg or any single IOP value exceeded 26 mmHg at any follow-up examination.

Postoperative IOP elevation was recorded in 16 eyes. Baseline mean IOP and diurnal IOP fluctuation were higher for the eleven eyes requiring medication before the three-month examination than for the other eyes (mean IOP: 28.8±5.2 mmHg versus 20.8±3.1 mmHg, unpaired t-test p<0.0001; IOP fluctuation: 9.5±3.7 mmHg versus 6.8±1.9 mmHg, p=0.0423). For the eyes with no medication, mean IOP decreased from 19.3±1.4 mmHg to 18.6±1.4 mmHg by month three and to 18.2±2.0 mmHg by month six. Diurnal fluctuation decreased from 7.2±2.3 mmHg to 4.3±1.7 mmHg by month three and to 5.1±1.7 mmHg by month six.

Dr Holló and co-workers concluded that SLT can result in significant decreases in mean diurnal IOP and fluctuation.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.